Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies.
Endoscopic treatment
Localized upper urinary tract urothelial carcinoma
Nephron-sparing surgery
Radical nephroureterectomy
Survival
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
09
12
2023
accepted:
06
05
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
Localized Upper Urinary Tract Urothelial Carcinoma (UTUC) is an uncommon cancer typically detected at an advanced stage. Currently, radical nephroureterectomy (RNU) with bladder cuff excision is the standard treatment for high-risk UTUC. This meta-analysis aims to evaluate the 5-year overall and cancer-specific survival and bladder recurrence rates in studies comparing endoscopic kidney-sparing surgeries (E-KSS) with RNU in localized UTUC. We performed a literature search on 20th April 2023 through PubMed, Web of Science, and Scopus. The PICOS model was used for study inclusion: P: adult patients with localized UTUC; I: E-KSS. C: RNU; O: primary: overall survival (OS); secondary: cancer-specific survival (CSS), bladder recurrence rate, and metastasis-free survival (MFS). S: retrospective, prospective, and randomized studies. Overall, 11 studies involving 2284 patients were eligible for this meta-analysis, 737 in the E-KSS group and 1547 in the RNU group. E-KSS showed a similar overall 5-year OS between E-KSS and RNU, and for low-grade tumors, while 5-year OS favored RNU for high-grade tumors (RR 1.84, 95% CI 1.26-2.69, p = 0.002). No difference emerged for 5-year CSS between the two groups, even when the results were stratified for low- and high grade tumors. Bladder recurrence rate and 5-year MFS were also similar between the two groups. Our review showed that E-KSS is a viable option for patients with localized UTUC with non-inferior oncological outcomes as compared with RNU, except for 5-year OS in high-grade tumors which favoured RNU.
Identifiants
pubmed: 38743260
doi: 10.1007/s00345-024-05032-y
pii: 10.1007/s00345-024-05032-y
doi:
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Comparative Study
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
318Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA: Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708
doi: 10.3322/caac.21708
pubmed: 35020204
Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Collaboration UTUCCUTUC (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115(6):1224–1233. https://doi.org/10.1002/cncr.24135
doi: 10.1002/cncr.24135
pubmed: 19156917
Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A (2010) Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 76(4):895–901. https://doi.org/10.1016/j.urology.2010.04.020
doi: 10.1016/j.urology.2010.04.020
pubmed: 20646743
Schuettfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Rink M, D’Andrea D, Abufaraj M, Karakiewicz PI, Shariat SF (2021) Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. Turkish J Urol 47(Supp. 1):S33–S44. https://doi.org/10.5152/tud.2020.20392
doi: 10.5152/tud.2020.20392
Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P (2023) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol 84(1):49–64. https://doi.org/10.1016/j.eururo.2023.03.013
doi: 10.1016/j.eururo.2023.03.013
pubmed: 36967359
Singla N, Hutchinson R, Menegaz C, Haddad AQ, Jiang L, Sagalowsky AI, Cadeddu JA, Lotan Y, Margulis V (2016) Comparing changes in renal function after radical surgery for upper tract urothelial carcinoma and renal cell carcinoma. Urology 96:44–53. https://doi.org/10.1016/j.urology.2016.07.015
doi: 10.1016/j.urology.2016.07.015
pubmed: 27443467
Seisen T, Colin P, Rouprêt M (2015) Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol 12(3):155–166. https://doi.org/10.1038/nrurol.2015.24
doi: 10.1038/nrurol.2015.24
pubmed: 25708579
Ham WS, Park JS, Jang WS, Kim J (2022) Nephron-sparing approaches in upper tract urothelial carcinoma: current and future strategies. Biomedicines 10(9):2223. https://doi.org/10.3390/biomedicines10092223
doi: 10.3390/biomedicines10092223
pubmed: 36140325
pmcid: 9496458
Yakoubi R, Colin P, Seisen T, Léon P, Nison L, Bozzini G, Shariat SF, Rouprêt M (2014) Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol 40(12):1629–1634. https://doi.org/10.1016/j.ejso.2014.06.007
doi: 10.1016/j.ejso.2014.06.007
pubmed: 25108813
Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF, Pierorazio PM, Potretzke AM, Psutka SP, Raman JD, Smith AB, Smith L (2023) Diagnosis and management of non-metastatic upper tract urothelial carcinoma: aUA/SUO guideline. J Urol 209(6):1071–1081. https://doi.org/10.1097/JU.0000000000003480
doi: 10.1097/JU.0000000000003480
pubmed: 37096584
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clin Res ed) 355:4919. https://doi.org/10.1136/bmj.i4919
doi: 10.1136/bmj.i4919
Chen YT, Yu CC, Yeh HC, Lee HY, Jiang YH, Lee YK, Kuei CH, Wu CC, Huang CY, Lin WY, Yang CK, Tsai YC (2021) Endoscopic management versus radical nephroureterectomy for localized upper tract urothelial carcinoma in a high endemic region. Sci Rep 11(1):4040. https://doi.org/10.1038/s41598-021-83495-4
doi: 10.1038/s41598-021-83495-4
pubmed: 33597574
pmcid: 7889610
Cutress ML, Stewart GD, Tudor EC, Egong EA, Wells-Cole S, Phipps S, Thomas BG, Riddick AC, McNeill SA, Tolley DA (2013) Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience. J Urol 189(6):2054–2060. https://doi.org/10.1016/j.juro.2012.12.006
doi: 10.1016/j.juro.2012.12.006
pubmed: 23228378
Seisen T, Nison L, Remzi M, Klatte T, Mathieu R, Lucca I, Bozzini G, Capitanio U, Novara G, Cussenot O, Compérat E, Renard-Penna R, Peyronnet B, Merseburger AS, Fritsche HM, Hora M, Shariat SF, Colin P, Rouprêt M (2016) Oncologic outcomes of kidney sparing surgery versus radical nephroureterectomy for the elective treatment of clinically organ confined upper tract urothelial carcinoma of the distal ureter. J Urol 195(5):1354–1361. https://doi.org/10.1016/j.juro.2015.11.036
doi: 10.1016/j.juro.2015.11.036
pubmed: 26612196
Shen CY, Jou YC, Kan WC, Tzai TS, Tsai YS (2022) Outcome of non-muscle invasive upper tract urothelial carcinoma receiving endoscopic ablation: an inverse probability of treatment weighting analysis. J Clin Med 11(5):1307. https://doi.org/10.3390/jcm11051307
doi: 10.3390/jcm11051307
pubmed: 35268398
pmcid: 8910842
Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K (2019) Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. World J Urol 37(6):1157–1164. https://doi.org/10.1007/s00345-018-2506-1
doi: 10.1007/s00345-018-2506-1
pubmed: 30267197
Fajkovic H, Klatte T, Nagele U, Dunzinger M, Zigeuner R, Hübner W, Remzi M (2013) Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experience. World J Urol 31(1):37–44. https://doi.org/10.1007/s00345-012-0948-4
doi: 10.1007/s00345-012-0948-4
pubmed: 23014836
Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS Jr (2010) Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 183(6):2148–2153. https://doi.org/10.1016/j.juro.2010.02.005
doi: 10.1016/j.juro.2010.02.005
pubmed: 20399468
Hoffman A, Yossepowitch O, Erlich Y, Holland R, Lifshitz D (2014) Oncologic results of nephron sparing endoscopic approach for upper tract low grade transitional cell carcinoma in comparison to nephroureterectomy - a case control study. BMC Urol 14:97. https://doi.org/10.1186/1471-2490-14-97
doi: 10.1186/1471-2490-14-97
pubmed: 25468319
pmcid: 4265434
Lee BR, Jabbour ME, Marshall FF, Smith AD, Jarrett TW (1999) 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes. J Endourol 13(4):289–294. https://doi.org/10.1089/end.1999.13.289
doi: 10.1089/end.1999.13.289
pubmed: 10405908
Lucas SM, Svatek RS, Olgin G, Arriaga Y, Kabbani W, Sagalowsky AI, Lotan Y (2008) Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int 102(2):172–176. https://doi.org/10.1111/j.1464-410X.2008.07535.x
doi: 10.1111/j.1464-410X.2008.07535.x
pubmed: 18341624
Raymundo EM, Lipkin ME, Bañez LB, Mancini JG, Zilberman DE, Preminger GM, Inman BA (2011) Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol 25(3):377–384. https://doi.org/10.1089/end.2010.0276
doi: 10.1089/end.2010.0276
pubmed: 21401392
Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, Shariat SF (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189(4):1214–1221. https://doi.org/10.1016/j.juro.2012.05.079
doi: 10.1016/j.juro.2012.05.079
pubmed: 23023150
Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX Jr, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF (2017) Upper urinary tract carcinoma in situ: current knowledge. Fut Dir J Urol 197(2):287–295. https://doi.org/10.1016/j.juro.2016.03.194
doi: 10.1016/j.juro.2016.03.194
Mazzaschi G, Giudice GC, Corianò M, Campobasso D, Perrone F, Maffezzoli M, Testi I, Isella L, Maestroni U, Buti S (2023) Upper tract urinary carcinoma: a unique immuno-molecular entity and a clinical challenge in the current therapeutic scenario. Technol Cancer Res Treat 22:15330338231159752. https://doi.org/10.1177/15330338231159753
doi: 10.1177/15330338231159753
pubmed: 36855829
pmcid: 9983117
Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35(3):379–387. https://doi.org/10.1007/s00345-016-1928-x
doi: 10.1007/s00345-016-1928-x
pubmed: 27604375
Yamany T, van Batavia J, Ahn J, Shapiro E, Gupta M (2015) Ureterorenoscopy for upper tract urothelial carcinoma: how often are we missing lesions? Urology 85(2):311–315. https://doi.org/10.1016/j.urology.2014.08.030
doi: 10.1016/j.urology.2014.08.030
pubmed: 25623674
Peyronnet B, Seisen T, Dominguez-Escrig JL, Bruins HM, Yuan CY, Lam T, Maclennan S, Ndow J, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Mostafid H, Rhijn BWG, Gontero P, Palou J, Shariat SF, Roupret M (2019) Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European association of urology guidelines systematic review. Eur Urol Focus 5(2):205–223. https://doi.org/10.1016/j.euf.2017.10.003
doi: 10.1016/j.euf.2017.10.003
pubmed: 29154042
Sui W, Wallis CJD, Luckenbaugh AN, Barocas DA, Chang SS, Penson DF, Resnick MJ, Laviana AA (2021) The impact of hospital volume on short-term and long-term outcomes for patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. Urology 147:135–142. https://doi.org/10.1016/j.urology.2020.07.062
doi: 10.1016/j.urology.2020.07.062
pubmed: 32891638
Kocher NJ, Canes D, Bensalah K, Roupret M, Lallas C, Margulis V, Shariat S, Colin P, Matin S, Tracy C, Xylinas E, Wagner A, Roumiguie M, Kassouf W, Klatte T, Raman JD (2020) Incidence and preoperative predictors for major complications following radical nephroureterectomy. Transl Androl Urol 9(4):1786–1793. https://doi.org/10.21037/tau.2020.01.22
doi: 10.21037/tau.2020.01.22
pubmed: 32944541
pmcid: 7475660
US Renal Data System (2018) USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Shariat SF, Upper Tract Urothelial Carcinoma Collaborative Group (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184(2):453–458. https://doi.org/10.1016/j.juro.2010.03.142
doi: 10.1016/j.juro.2010.03.142
pubmed: 20620397
Simonato A, Varca V, Gregori A, Benelli A, Ennas M, Lissiani A, Gacci M, De Stefani S, Rosso M, Benvenuto S, Siena G, Belgrano E, Gaboardi F, Carini M, Bianchi G, Carmignani G (2012) Elective segmental ureterectomy for transitional cell carcinoma of the ureter: long-term follow-up in a series of 73 patients. BJU Int 110(11 Pt B):E744–E749. https://doi.org/10.1111/j.1464-410X.2012.11554.x
doi: 10.1111/j.1464-410X.2012.11554.x
pubmed: 23134540
Motamedinia P, Keheila M, Leavitt DA, Rastinehad AR, Okeke Z, Smith AD (2016) The expanded use of percutaneous resection for upper tract urothelial carcinoma: a 30-year comprehensive experience. J Endourol 30(3):262–267. https://doi.org/10.1089/end.2015.0248
doi: 10.1089/end.2015.0248
pubmed: 26630130
Grasso M, Fishman AI, Cohen J, Alexander B (2012) Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int 110(11):1618–1626. https://doi.org/10.1111/j.1464-410X.2012.11066.x
doi: 10.1111/j.1464-410X.2012.11066.x
pubmed: 22458598
Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, Shariat SF, Rouprêt M (2016) Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-muscle invasive bladder cancer guidelines panel. Eur Urol 70(6):1052–1068. https://doi.org/10.1016/j.eururo.2016.07.014
doi: 10.1016/j.eururo.2016.07.014
pubmed: 27477528
Lonergan PE, Porten SP (2020) Bladder tumor recurrence after urothelial carcinoma of the upper urinary tract. Transl Androl Urol 9(4):1891–1896. https://doi.org/10.21037/tau.2020.03.47
doi: 10.21037/tau.2020.03.47
pubmed: 32944553
pmcid: 7475654
Lucca I, Klatte T, Rouprêt M, Shariat SF (2015) Kidney-sparing surgery for upper tract urothelial cancer. Curr Opin Urol 25(2):100–104. https://doi.org/10.1097/MOU.0000000000000148
doi: 10.1097/MOU.0000000000000148
pubmed: 25581542
Taratkin M, Singla N, Babaevskaya D, Androsov A, Shariat SF, Fajkovic H, Baniel J, Enikeev D (2023) A review of how lasers are used in UTUC surgery: can the choice of laser affect outcomes? Cancers 15(6):1874. https://doi.org/10.3390/cancers15061874
doi: 10.3390/cancers15061874
pubmed: 36980763
pmcid: 10047311
Kleinmann N, Matin SF, Pierorazio PM, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky S, Rivera M, O’Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Stern J, Weight C, Weizer A, Woods M, Kaimakliotis H, Lerner SP (2020) Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol 21(6):776–785. https://doi.org/10.1016/S1470-2045(20)30147-9
doi: 10.1016/S1470-2045(20)30147-9
pubmed: 32631491
Knoedler JJ, Raman JD (2018) Advances in the management of upper tract urothelial carcinoma: improved endoscopic management through better diagnostics. Ther Adv Urol 10(12):421–429. https://doi.org/10.1177/1756287218805334
doi: 10.1177/1756287218805334
pubmed: 30574202
pmcid: 6295784